Faeth Therapeutics (FTH) Liabilities and Shareholders Equity (2020 - 2026)

Faeth Therapeutics (FTH) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $145.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $145.4 million; the trailing twelve-month figure through Jun 2026 stood at $401.3 million (up 306.89% YoY), and the FY2025 full-year result was $22.9 million, down 49.51% from the prior year.
• Liabilities and Shareholders Equity fell to $145.4 million in Q2 2026 per FTH's latest filing, from $205.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $205.4 million in Q1 2026 and bottomed at $22.9 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $94.7 million across 5 years, with a median of $85.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity dropped 14.01% in 2022, then sank 49.51% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $118.4 million in 2022, then sank by 37.17% to $74.4 million in 2023, then slumped by 39.01% to $45.4 million in 2024, then tumbled by 49.51% to $22.9 million in 2025, then surged by 534.81% to $145.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $145.4 million, $205.4 million, and $22.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.